RXST

Company Overview — What Does RxSight, Inc. Do?

RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California. RxSight, Inc. (RXST) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Ronald M. Kurtz and employs approximately 220 people. With a market capitalization of $262M, RXST is one of the notable companies in the Healthcare sector.

RxSight, Inc. (RXST) Stock Rating — Reduce (April 2026)

As of April 2026, RxSight, Inc. receives a Reduce rating with a composite score of 28.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.RXST ranks #3,715 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, RxSight, Inc. ranks #617 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

RXST Stock Price and 52-Week Range

RxSight, Inc. (RXST) currently trades at $6.83. The stock gained $0.06 (0.9%) in the most recent trading session. The 52-week high for RXST is $27.13, which means the stock is currently trading -74.8% from its annual peak. The 52-week low is $6.32, putting the stock 8.1% above its annual trough. Recent trading volume was 423K shares, suggesting relatively thin trading activity.

Is RXST Overvalued or Undervalued? — Valuation Analysis

RxSight, Inc. (RXST) carries a value factor score of 20/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.01x, versus the sector average of 2.75x. The price-to-sales ratio is 2.03x, compared to 1.66x for the average Healthcare stock.

At current multiples, RxSight, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

RxSight, Inc. Profitability — ROE, Margins, and Quality Score

RxSight, Inc. (RXST) earns a quality factor score of 36/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -13.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -11.6% versus the sector average of -33.1%.

On a margin basis, RxSight, Inc. reports gross margins of 75.2%, compared to 71.5% for the sector. The operating margin is -34.0% (sector: -66.1%). Net profit margin stands at -26.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -13.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

RXST Debt, Balance Sheet, and Financial Health

RxSight, Inc. has a debt-to-equity ratio of 13.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 10.95x, indicating strong short-term liquidity. Total debt on the balance sheet is $10M. Cash and equivalents stand at $30M.

RXST has a beta of 1.38, meaning it is more volatile than the broader market — a $10,000 investment in RXST would be expected to move 38.2% more than the S&P 500 on any given day. The stability factor score for RxSight, Inc. is 27/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

RxSight, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, RxSight, Inc. reported revenue of $137M and earnings per share (EPS) of $-0.95. Net income for the quarter was $-36M. Gross margin was 75.2%. Operating income came in at $-46M.

In FY 2025, RxSight, Inc. reported revenue of $134M and earnings per share (EPS) of $-0.95. Net income for the quarter was $-39M. Gross margin was 76.6%. Revenue grew -3.9% year-over-year compared to FY 2024. Operating income came in at $-48M.

In Q3 2025, RxSight, Inc. reported revenue of $30M and earnings per share (EPS) of $-0.24. Net income for the quarter was $-10M. Gross margin was 79.8%. Revenue grew -14.1% year-over-year compared to Q3 2024. Operating income came in at $-12M.

In Q2 2025, RxSight, Inc. reported revenue of $34M and earnings per share (EPS) of $-0.29. Net income for the quarter was $-12M. Gross margin was 74.9%. Revenue grew -3.6% year-over-year compared to Q2 2024. Operating income came in at $-14M.

Over the past 8 quarters, RxSight, Inc. has demonstrated a growth trajectory, with revenue expanding from $35M to $137M. Investors analyzing RXST stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

RXST Dividend Yield and Income Analysis

RxSight, Inc. (RXST) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

RXST Momentum and Technical Analysis Profile

RxSight, Inc. (RXST) has a momentum factor score of 15/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 37/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 50/100 reflects moderate short selling activity.

RXST vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, RxSight, Inc. (RXST) ranks #617 out of 838 stocks based on the Blank Capital composite score. This places RXST in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing RXST against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full RXST vs S&P 500 (SPY) comparison to assess how RxSight, Inc. stacks up against the broader market across all factor dimensions.

RXST Next Earnings Date

No upcoming earnings date has been announced for RxSight, Inc. (RXST) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy RXST? — Investment Thesis Summary

The quantitative profile for RxSight, Inc. suggests caution. The quality score of 36/100 flags below-average profitability. The value score of 20/100 indicates premium valuation. Momentum is weak at 15/100, a headwind for near-term performance. High volatility (stability score 27/100) increases portfolio risk.

In summary, RxSight, Inc. (RXST) earns a Reduce rating with a composite score of 28.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on RXST stock.

Related Resources for RXST Investors

Explore more research and tools: RXST vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare RXST head-to-head with peers: RXST vs AZN, RXST vs SLGL, RXST vs VMD.